Does delaying curative surgery for colorectal cancer influence long-term disease-free survival? A cohort study - Scorecard - MDSpire

Does delaying curative surgery for colorectal cancer influence long-term disease-free survival? A cohort study

  • By

  • Stephanie Garcia-Botello

  • J. Martín-Arevalo

  • C. Cozar-Lozano

  • A. Benitez-Riesco

  • D. Moro-Valdezate

  • V. Pla-Martí

  • A. Espí-Macías

  • July 11, 2021

  • 0 min

Share

Clinical Scorecard: The Impact of Postponing Curative Surgery on Long-Term Disease-Free Survival in Colorectal Cancer: A Cohort Analysis

At a Glance

CategoryDetail
ConditionColorectal cancer (AJCC stage I–III)
Key MechanismsEffect of wait list time (WLT) from diagnosis to definitive surgery on long-term disease-free survival (DFS)
Target PopulationPatients with stage I–III colorectal adenocarcinoma scheduled for curative resection without neoadjuvant chemoradiotherapy
Care SettingTertiary hospital colorectal surgery unit with standard multimodal enhanced recovery care

Key Highlights

  • Median wait list time (WLT) was 28 days; WLT divided into 2-week intervals up to >6 weeks for analysis.
  • Two-year and five-year disease-free survival rates were 86.5% and 83.1%, respectively, in 602 patients.
  • Conflicting evidence exists on impact of surgical delay; some studies suggest delays beyond 3–6 weeks may reduce survival.

Guideline-Based Recommendations

Diagnosis

  • Complete diagnostic workup includes colonoscopy with biopsy and abdominal CT for colon cancer.
  • For rectal tumors, add rigid proctoscopy, pelvic MRI, and endorectal ultrasound.
  • Fast-track oncological diagnostic circuit typically takes 7–10 days.

Management

  • Surgery scheduled based on urgency; emergency cases (obstruction, perforation) require immediate treatment.
  • Early-stage cases may be deferred during crises like COVID-19; advanced cases may have prolonged neoadjuvant therapy.
  • Standard adjuvant chemotherapy administered 6 weeks post-surgery for stage III and high-risk stage II tumors.

Monitoring & Follow-up

  • Postoperative disease progression monitored by 6-monthly serum carcinoembryonic antigen (CEA) levels.
  • Chest and abdominal CT scans performed after CEA elevation or annually if CEA normal.

Risks

  • Delays beyond 3–6 weeks may be associated with decreased 5-year survival in stage I–III colon cancer.
  • Emergency surgery excluded due to higher risk and confounding factors.
  • Postoperative complications and patient comorbidities impact outcomes and should be considered.

Patient & Prescribing Data

602 patients with AJCC stage I–III colorectal adenocarcinoma undergoing curative surgery without neoadjuvant therapy

Median WLT was 28 days; majority underwent laparoscopic surgery; 2- and 5-year DFS rates were high, suggesting timely surgery within 6 weeks is associated with favorable outcomes.

Clinical Best Practices

  • Prioritize surgical treatment within 3–6 weeks of diagnosis when possible to optimize long-term DFS.
  • Use multidisciplinary triage during healthcare crises to balance urgency and resource availability.
  • Employ enhanced recovery protocols pre- and postoperatively to improve outcomes.
  • Monitor patients closely postoperatively with CEA and imaging to detect recurrence early.
  • Consider patient comorbidities and tumor stage in surgical timing decisions.

References

Original Source(s)

Related Content